{"product_id":"imodium-8-capsule-2mg-acquista-online-su-farmaclick","title":"Imodium 8 Capsules 2mg | Buy Online at Farmaclick","description":"\u003ch3\u003eImodium 8 capsules 2mg\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003cbr\u003e\u003c\/strong\u003eLoperamide hydrochloride.\u003cbr\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003cbr\u003eHard capsules 2 mg: lactose, corn starch, talc, magnesium stearate. A grey-green hard capsule consists of: erythrosine (E 127); indigotine (E 132); yellow iron oxide (E 172); black iron oxide (E 172); titanium dioxide and gelatin q.s. per capsule. Effervescent tablets 2 mg: anhydrous citric acid, sodium bicarbonate, sodium chloride, potassium chloride, anhydrous glucose, sorbitol, macrogol 6000, sodium saccharin, powdered lemon flavour. Orodispersible tablets 2 mg: gelatin, mannitol, aspartame, mint flavour, sodium bicarbonate.\u003cbr\u003eSoft capsules 2 mg. Capsule content: propylene glycol monocaprylate, propylene glycol, distilled water. Capsule shell: gelatin, 99% glycerol, propylene glycol, FD\u0026amp;C blue no. 1.\u003cbr\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003cbr\u003eSymptomatic treatment of acute diarrhoea.\u003cbr\u003e\u003cstrong\u003eCONTRAINDICATIONS\/ADVERSE EFFECTS\u003c\/strong\u003e\u003cbr\u003eDo not use in children under 6 years of age; pregnancy and breastfeeding. Loperamide HCl should not be used as primary therapy in acute dysentery characterized by blood in the stools and high fever. Furthermore, it must not be administered to patients with acute ulcerative colitis or pseudomembranous colitis due to the use of broad-spectrum antibiotics, nor must it be administered to patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella and Campylobacter. In general, the use of Loperamide HCl is contraindicated in all cases where inhibition of peristalsis must be avoided due to the possible risk of significant consequences such as ileus, megacolon and toxic megacolon. If constipation, abdominal distension or sub-ileus occur, discontinue treatment immediately.\u003cbr\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003cbr\u003eAdults and children aged between 6 and 17 years. Hard capsules 2 mg: the initial dose is 2 capsules (4 mg) for adults and 1 capsule (2 mg) for children to be taken by mouth with some liquid. Effervescent tablets 2 mg: the initial dose is 2 effervescent tablets (4 mg) for adults and 1 effervescent tablet (2 mg) for children, to be taken dissolved in a glass of water. Orodispersible tablets 2 mg: the initial dose is 2 orodispersible tablets (4 mg) for adults and 1 orodispersible tablet (2 mg) for children to be left to dissolve on the tongue for a few seconds. Soft capsules 2 mg: the initial dose is 2 soft capsules (4 mg) for adults and 1 soft capsule (2 mg) to be taken by mouth with some liquid. Thereafter, 1 capsule or 1 effervescent tablet or 1 orodispersible tablet (2 mg) or 1 soft capsule (2 mg) after each subsequent evacuation of unformed (soft) stools. For adults, the maximum daily dose is 8 capsules or tablets per day (16 mg). For children, the dose must be related to body weight (3 capsules or tablets\/20 kg) but must not exceed a maximum of 8 tablets per day. Do not use for more than 2 days. In fact, in episodes of acute diarrhoea, Loperamide HCl is generally able to stop symptoms within 48 hours. After this period without appreciable results, discontinue treatment and consult a physician. In any case, treatment should be discontinued upon normalization of stools, or if there have been no bowel movements for 12 hours, or if constipation occurs. Elderly: no dose adjustment is necessary. Renal impairment: no dose adjustment is necessary. Hepatic impairment: although no data are available for patients with hepatic impairment, Loperamide HCl should be used with caution in these patients due to reduced first-pass metabolism.\u003cbr\u003e\u003cstrong\u003eSTORAGE\u003c\/strong\u003e\u003cbr\u003eStore in the original packaging to protect the medicine from moisture. Soft capsules: do not store above 25°C. Keep the blister in the original packaging to protect the medicine from light.\u003cbr\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003cbr\u003eTreatment of diarrhoea with Loperamide HCl is symptomatic only. Therefore, where possible, it is appropriate to also address the causes of the disorder. In patients with diarrhoea, especially in children, fluid and electrolyte depletion may occur. In such cases, it may be very important to appropriately replace the fluids and electrolytes themselves. For this reason, the effervescent tablets contain the elements to replace such losses. Each effervescent tablet provides 500 mg of Glucose and the following electrolyte intake: sodium 260 mg (11.3 meq); potassium 80 mg (2.0 meq); chloride 234 mg (6.6 meq). Each effervescent tablet contains 0.5 g of glucose: this should be taken into account for subjects suffering from diabetes. It is advisable to discontinue treatment with Loperamide HCl if there is no improvement in clinical symptoms within 48 hours of the start of therapy. Loperamide is subject to intense first-pass metabolism. The drug should be used with caution in patients with hepatic impairment as it may lead to a relative overdose with CNS toxicity. Patients with AIDS treated with Loperamide HCl for diarrhoea must discontinue therapy at the first sign of abdominal distension. In these patients with infectious colitis of bacterial or viral origin treated with loperamide hydrochloride, isolated cases of constipation with an increased risk of toxic megacolon have been observed. Hard capsules contain lactose. Effervescent tablets contain sorbitol and glucose. In children between 6 and 12 years of age, the medicine must be used exclusively under medical supervision. Hard capsules: 8 capsules - swallow the capsules with a little water. Effervescent tablets: 10 tablets - dissolve the effervescent tablet in a glass of water. Orodispersible tablets: 12 tablets - place the tablet on the tongue. The tablet will be dissolved quickly by saliva. Orodispersible tablets do not require water. Soft capsules: 12 soft capsules - swallow the capsules with a little water.\u003cbr\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003cbr\u003eNon-clinical data have shown that loperamide is a P-glycoprotein substrate. Concomitant administration of loperamide (in a single 16 mg dose) with quinidine or ritonavir (both P-glycoprotein inhibitors) has shown 2- to 3-fold increases in plasma loperamide levels. The clinical relevance of this pharmacokinetic interaction with P-glycoprotein inhibitors when loperamide is administered at recommended doses (2 to a maximum of 16 mg per day) is unknown. Concomitant administration of loperamide (in a single 4 mg dose) and itraconazole, a CYP3A4 and P-glycoprotein inhibitor, has shown a 3- to 4-fold increase in plasma loperamide levels. In the same study, gemfibrozil, a CYP2C8 inhibitor, showed a 2-fold increase in plasma loperamide levels. The combination of itraconazole and gemfibrozil showed a 4-fold increase in peak plasma loperamide levels and a 13-fold increase in total plasma exposure. These increases were not associated with effects on the central nervous system (CNS) as detected by psychomotor tests (e.g., subjective dizziness and the Digit Symbol Substitution Test). Concomitant administration of loperamide (in a single 16 mg dose) and ketoconazole, a CYP3A4 and P-glycoprotein inhibitor, showed a 5-fold increase in plasma loperamide levels. This increase was not associated with increased pharmacodynamic effects as detected by pupillometry. Concomitant treatment with oral desmopressin resulted in a 3-fold increase in plasma desmopressin concentrations, presumably due to slowed gastrointestinal motility. Concomitant use of CYP450 cytochrome inhibitors is not recommended. Concomitant treatment with substances with similar pharmacological properties may potentiate the effect of loperamide, and substances that accelerate gastrointestinal transit may decrease its effect. Interactions are possible with drugs having pharmacological properties similar to those of loperamide or drugs that may slow intestinal peristalsis (e.g., anticholinergics), as the effects of the drug could be potentiated.\u003cbr\u003e\u003cstrong\u003e\u003cbr\u003eSIDE EFFECTS\u003c\/strong\u003e\u003cbr\u003eAdults and children aged \u0026gt;=12 years: acute diarrhoea and chronic diarrhoea. The most commonly reported adverse drug reactions (ADRs) (i.e., with an incidence \u0026gt;=1%) in clinical trials with Loperamide HCl for the treatment of acute diarrhoea were: constipation, flatulence, headache, and nausea. In clinical trials for the treatment of chronic diarrhoea, the most commonly reported ADRs (i.e., \u0026gt;=1% incidence) were: flatulence, constipation, nausea, and dizziness. Below are the ADRs that have been reported with the use of Loperamide HCl both in clinical trials (in cases of acute or chronic diarrhoea, or both) and in post-marketing experience. By convention, based on their frequency, side effects have been divided into the following categories: very common (\u0026gt;=1\/10); common (\u0026gt;=1\/100 to \u0026lt;1\/10); uncommon (\u0026gt;=1\/1,000 to \u0026lt;1\/100); rare (\u0026gt;=1\/10,000 to \u0026lt;1\/1,000); and very rare (\u0026lt;1\/10,000).\u003cbr\u003eAcute diarrhoea. Nervous system disorders. Common: headache; uncommon: dizziness. Gastrointestinal disorders. Common: constipation, nausea, flatulence; uncommon: abdominal pain, abdominal discomfort, dry mouth, upper abdominal pain, vomiting; rare: abdominal distension. Skin and subcutaneous tissue disorders. Uncommon: rash.\u003cbr\u003eChronic diarrhoea. Nervous system disorders. Uncommon: headache; common: dizziness. Gastrointestinal disorders. Common: constipation, nausea, flatulence; uncommon: abdominal pain, abdominal discomfort, dry mouth, dyspepsia.\u003cbr\u003eAcute + chronic diarrhoea and post-marketing experience. Immune system disorders. Rare: hypersensitivity reaction, anaphylactic reaction (including anaphylactic shock), anaphylactoid reaction. Nervous system disorders. Common: headache, dizziness; uncommon: drowsiness; rare: loss of consciousness, stupor, depressed level of consciousness, hypertonia, coordination disorder. Eye disorders. Rare: miosis. Gastrointestinal disorders. Common: constipation, nausea, flatulence; uncommon: abdominal pain, abdominal discomfort, dry mouth, upper abdominal pain, vomiting, dyspepsia; rare: ileus (including paralytic ileus), megacolon (including toxic megacolon), glossodynia, abdominal distension. Skin and subcutaneous tissue disorders. Uncommon: rash; rare: bullous eruption (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme), angioedema, urticaria, pruritus. Renal and urinary disorders. Rare: urinary retention. General disorders and administration site conditions. Rare: fatigue. For ADRs reported during clinical trials for which frequency is not presented, the term was not observed nor considered an ADR for this indication. Children: the safety of Loperamide HCl was evaluated in 607 patients aged between 10 days and 13 years who took part in 13 controlled and uncontrolled clinical trials with Loperamide HCl used for the treatment of acute diarrhoea. In general, the ADR profile in this patient population was similar to that observed in clinical trials with Loperamide HCl used in adults and adolescents 12 years of age and older. Reporting suspected adverse reactions after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product.\u003cbr\u003e\u003cstrong\u003e\u003cbr\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003cbr\u003eAdministration of the product during pregnancy is not recommended. Pregnant or breastfeeding women must therefore consult a physician for appropriate treatment.\u003c\/p\u003e","brand":"SalusMarket Salute e Benessere Online","offers":[{"title":"Default Title","offer_id":53444124475734,"sku":"44535019","price":8.0,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0968\/4507\/0678\/files\/Imodium-8-capsule-2mg-044535019_rx0g-qn_8dee6c03-0ac7-4d28-8975-1fa8b5209bb7.webp?v=1778160089","url":"https:\/\/farmasmart.shop\/en\/products\/imodium-8-capsule-2mg-acquista-online-su-farmaclick","provider":"SalusMarket Salute e Benessere Online","version":"1.0","type":"link"}